12:42 PM EDT, 04/03/2024 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Wednesday said Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the University Health Network (UHN), has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The UHN clinical team has submitted an application to the local ethics board for permission to participate in the trial.

The addition of UHN as the second Canadian hospital site increases the number of trial sites to eight, with six active clinical sites in Turkey, the statement added.

LSALT peptide is Arch's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. The CS-AKI Phase II trial is an international multi-center study of LSALT peptide, with a recruitment target of 240 patients. The primary objective is to evaluate the percentage of subjects with AKI within seven days following on-pump (heart-lung machine) cardiac surgery.

Arch shares were last seen up C$0.04 to C$2.43 on the TSX Venture Exchange.

Price: 2.43, Change: +0.04, Percent Change: +1.67